Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single DOAC level measurement and dose adjustment in frail older patients
NL-OMON60891Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Composite of thromboembolic events or bleeding. Started Jan 2026; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON60891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60891.